WO2009069447A1 - インフルエンザワクチン用のアジュバント及びインフルエンザワクチン - Google Patents

インフルエンザワクチン用のアジュバント及びインフルエンザワクチン Download PDF

Info

Publication number
WO2009069447A1
WO2009069447A1 PCT/JP2008/070281 JP2008070281W WO2009069447A1 WO 2009069447 A1 WO2009069447 A1 WO 2009069447A1 JP 2008070281 W JP2008070281 W JP 2008070281W WO 2009069447 A1 WO2009069447 A1 WO 2009069447A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleotides
influenza vaccine
length
adjuvant
residue
Prior art date
Application number
PCT/JP2008/070281
Other languages
English (en)
French (fr)
Inventor
Tomokatsu Iwamura
Chikateru Nozaki
Kazuyoshi Kaminaka
Junichi Matsuda
Original Assignee
Toray Industries, Inc.
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries, Inc., Juridical Foundation The Chemo-Sero-Therapeutic Research Institute filed Critical Toray Industries, Inc.
Publication of WO2009069447A1 publication Critical patent/WO2009069447A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

　本発明は、インターフェロン（ＩＦＮ）誘導活性が増強され、かつ炎症性サイトカイン誘導活性が低減された新規な免疫刺激オリゴヌクレオチドをアジュバントとして含む、インフルエンザワクチンを提供することを目的とする。本発明は、５’－（Ｇ）MＰＸＣＧＹＱ（Ｇ）N－３’［式中、Ｃは、シトシン、Ｇは、グアニン、Ｘ及びＹは、それぞれ独立に、４塩基以上連続したグアニンを含まない０～１０ヌクレオチド長の塩基配列（但し、Ｘ＋Ｙの長さは、６～２０ヌクレオチド長である。）、ＸＣＧＹは、少なくとも８ヌクレオチド長のパリンドローム配列を含む８～２２ヌクレオチド長の塩基配列、Ｐ及びＱは、それぞれ独立に、グアニン以外の１ヌクレオチド、Ｍは、６～１０の整数、Ｎは、０～３の整数を表す。］で示され、全長が１６～３７ヌクレオチド長のオリゴヌクレオチドである（但し、配列表の配列番号５記載の塩基配列からなるものは除く。）、インフルエンザワクチン用のアジュバントを提供する。
PCT/JP2008/070281 2007-11-28 2008-11-07 インフルエンザワクチン用のアジュバント及びインフルエンザワクチン WO2009069447A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007307931 2007-11-28
JP2007-307931 2007-11-28

Publications (1)

Publication Number Publication Date
WO2009069447A1 true WO2009069447A1 (ja) 2009-06-04

Family

ID=40678349

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/070281 WO2009069447A1 (ja) 2007-11-28 2008-11-07 インフルエンザワクチン用のアジュバント及びインフルエンザワクチン

Country Status (1)

Country Link
WO (1) WO2009069447A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011136738A1 (en) 2010-04-30 2011-11-03 Temasek Life Sciences Laboratory Limited Universal vaccine against h5n1 lineages
US11578331B2 (en) 2015-09-09 2023-02-14 Gilead Sciences, Inc. Combination comprising immunostimulatory oligonucleotides
US11583581B2 (en) 2015-09-21 2023-02-21 Gilead Sciences, Inc. Methods of treating a retroviral infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005083076A1 (ja) * 2004-02-27 2005-09-09 Emori & Co., Ltd. インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
WO2006035939A1 (ja) * 2004-09-30 2006-04-06 Osaka University 免疫刺激オリゴヌクレオチドおよびその医薬用途
WO2006108358A1 (fr) * 2005-04-13 2006-10-19 Changchun Huapu Biotechnology Co., Ltd. UTILISATION ANTIVIRALE D’OLIGODESOXYNUCLEOTIDES ARTIFICIELS A UN SEUL BRIN CONTENANT UN CpG EN COMBINAISON AVEC LA RIBAVIRINE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005083076A1 (ja) * 2004-02-27 2005-09-09 Emori & Co., Ltd. インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
WO2006035939A1 (ja) * 2004-09-30 2006-04-06 Osaka University 免疫刺激オリゴヌクレオチドおよびその医薬用途
WO2006108358A1 (fr) * 2005-04-13 2006-10-19 Changchun Huapu Biotechnology Co., Ltd. UTILISATION ANTIVIRALE D’OLIGODESOXYNUCLEOTIDES ARTIFICIELS A UN SEUL BRIN CONTENANT UN CpG EN COMBINAISON AVEC LA RIBAVIRINE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAMSTRUP, S. ET AL.: "Response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides", VET MICROBIOL, vol. 78, no. 4, 2001, pages 353 - 362 *
YAMAMOTO, S. ET AL.: "Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity", J IMMUNOL, vol. 148, no. 12, 1992, pages 4072 - 4076 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011136738A1 (en) 2010-04-30 2011-11-03 Temasek Life Sciences Laboratory Limited Universal vaccine against h5n1 lineages
US11578331B2 (en) 2015-09-09 2023-02-14 Gilead Sciences, Inc. Combination comprising immunostimulatory oligonucleotides
US11583581B2 (en) 2015-09-21 2023-02-21 Gilead Sciences, Inc. Methods of treating a retroviral infection

Similar Documents

Publication Publication Date Title
WO2005108411A3 (en) Substituted pixyl protecting groups for oligonucleotide synthesis
JP2010519915A5 (ja)
ATE538127T1 (de) 6-disubstituierte bicyclische nukleinsäureanaloga
AU2008309264A8 (en) Immune stimulatory oligonucleotide analogs containing modified sugar moieties
WO2009061941A3 (en) Baseless nucleotide analogues and uses thereof
NO20082934L (no) Antivirale nukleotider
MX356830B (es) Adyuvante de acido nucleico quiral.
TW200800995A (en) Novel pharmaceuticals
NO20091218L (no) CPG-oligonukleotidanaloger inneholdende hydrofobe T-analoger med forbedret immunstimulatorisk aktivitet
WO2007062160A3 (en) Methods and compositions for sequencing a nucleic acid
WO2005042018A3 (en) C-class oligonucleotide analogs with enhanced immunostimulatory potency
WO2007140506A8 (en) Modified microbial nucleic acid for use in detection and analysis of microorganisms
WO2005007875A3 (en) Enhanced promoters for synthesis of small hairpin rna
WO2007147067A3 (en) Methods and compositions for regulating cell cycle progression
RU2012100248A (ru) Аптамер к химазе и его применение
IL145797A0 (en) Production of attenuated negative stranded rna virus vaccines from cloned nucleotide sequences
WO2010040033A4 (en) Methods and compositions for modulating an immune response with immunogenic oligonucleotides
WO2009069447A1 (ja) インフルエンザワクチン用のアジュバント及びインフルエンザワクチン
WO2008142513A3 (en) Phosphate-modified oligonucleotide analogs with immunostimulatory activity
EP1892293A4 (en) TRANSCRIPTION FACTOR DECOY
AU2003291931A8 (en) Novel buffer formulations for isolating, purifying and recovering long-chain and short-chain nucleic acids
EP1209228A3 (en) Environmental stress responsive promoter
DK1644389T3 (da) Pyrinidinforbindelser med phosphonatgrupper som antivirale nukleotidanaloger
WO2003068969A1 (en) Mouse spermatogenesis genes, human male sterility-associated genes and diagnostic system using the same
MXPA04004621A (es) Nucleotidos, preparaciones de los mismos y su utilizacion como inhibidores de polimerasas virales de arn.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08855009

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08855009

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP